GSK's shares declined more than 2% on Tuesday following the announcement that the company agreed to buy Nuvalent Inc. for $10.6 billion. The deal, revealed on June 9, sets a price of $124 per Nuvalent share - representing a 40% premium to the stock's most recent closing price and its 30-day volume-weighted average price. After factoring in cash on Nuvalent's balance sheet, GSK's stated net investment in the transaction is $9.4 billion.
Deal rationale and portfolio focus
The acquisition is focused on three lung cancer programs. Two of these, zidesamtinib (NVL-520) and neladalkib (NVL-655), are highly selective inhibitors targeting ROS1 and ALK for non-small cell lung cancer (NSCLC). Both candidates have received FDA Breakthrough Therapy and Orphan Drug designations. The U.S. regulator has set target decision dates in 2026 for both therapies, with zidesamtinib scheduled first and neladalkib set for a Nov. 27 decision. A third asset in the deal, NVL-330, is directed at HER2-altered NSCLC and remains in Phase I clinical testing, according to regulatory filings.
On a media call, GSK chief executive Luke Miels defended the transaction's price, noting that the size reflected the unusual opportunity to secure multiple products in a single deal. He said the deal size was "larger than usual" because it was "unusual" to get multiple products in one deal, and added he was "convinced that this was a deal that we needed to do." Miels also said GSK is working to offset the cost of servicing the debt from deal financing.
Nuvalent chief executive James Porter said GSK's "proven track record, infrastructure" would support "successful commercialisation of zidesamtinib and neladalkib."
Financial and timing implications
GSK indicated the acquisition will begin contributing to revenue from 2027. The company expects the deal to be accretive to core operating profit and core earnings per share by 2029, after accounting for synergies and any reprioritisation of resources. The filing makes clear that GSK does not require this deal to meet its longer-term sales goal, with Miels stating the company does not need the Nuvalent transaction to reach its £40 billion sales target by 2031. Nonetheless, the filing also notes the acquisition is expected to strengthen GSK's ambition for sales of more than £40 billion by 2031.
For near-term guidance, GSK confirmed there is no change to its full-year 2026 outlook, maintaining a 7% to 9% range for core operating profit growth. The company cautioned investors that it expects a low-single-digit percentage dilution to core EPS across 2026, 2027 and 2028 as the business integrates the deal.
Under existing revenue-sharing arrangements, GSK will pay low-single-digit royalties to Royalty Pharma. The transaction is to be financed primarily through a combination of new and existing debt facilities; GSK said it will retain a strong investment-grade credit profile and reiterated its expectation to pay a 70 pence dividend for 2026.
Deal mechanics and regulatory conditions
The agreement is structured as a tender offer for all outstanding Class A and Class B Nuvalent shares, which GSK plans to launch within 10 business days. That initial tender will be followed by a second-step merger at the same price. The closing of the transaction is subject to customary regulatory review, including antitrust clearance under the Hart-Scott-Rodino Act.
Market reaction
Investors reacted to the announcement with a decline in GSK's share price, reflecting investor focus on the size of the payout, near-term dilution expectations and the financing required to complete the deal. For Nuvalent shareholders, the $124 per share proposal represents a material premium to recent trading levels.
As the companies proceed with the tender offer and await regulatory approvals, the market will continue to watch timelines for FDA decisions on the two late-stage candidates and the company's progress on financing and integration plans.